|
|
|
| Purification, Characterization and Pharmacokinetic Study of a Novel Long-acting Follicle-stimulating Hormone |
| YANG Fan1, HUANG Hu1, LI Yi-chen2, DENG Heng-lu2, WU Mao-bo2, ZHONG Ling1,3, HOU Yong-min1,2 |
1. School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China;
2. Unicomed Pharma Ltd., Guangzhou 510006, China;
3. Shenzhen Drug Administration, Shenzhen 518024, China |
|
|
|
Abstract Follicle-stimulating hormone (FSH) has been utilized to treat male and female infertility. However, frequent injection of FSH to patients is required due to its short serum half-life. Developing a long-acting recombinant FSH is clinically desirable. A DNA construct containing FSH-CTP-vFc was made by fusing the coding sequence of carboxyl-terminal peptide (CTP) of the β-subunit of human chorionic gonadotropin and a variant of human Immunoglobulin G2(IgG2) Fc fragment (vFc) into FSH gene. The DNA construct was transfected into Chinese Hamster Ovary (CHO) cells, and cell clones with highly and stably expressed FSH-CTP-vFc fusion protein were selected. The cultured medium of cell was collected for protein purification by protein A based chromatography. Biochemical and physical characterization were performed for the fusion proteins purified from the samples of different culture time. ELISA assay and animal study shows that the purified FSH-CTP-vFc protein has significant activity in vitro and in vivo. Pharmacokinetic research demonstrates that the serum half-life of the fusion protein is almost ten fold of the recombinant FSH's. Obviously, this novel long-acting FSH-CTP-vFc protein could greatly reduce the injection frequency and improve the patient compliance.
|
|
Received: 03 December 2013
Published: 25 February 2014
|
|
|
|
|
[1] 范俊,邓晓惠. 卵泡刺激素研究进展.生殖与避孕, 1998, 18(2): 122-125. Fan J, Deng X H. Research progress of follicle stimulating hormone. Journal of Reproduction and Contraception, 1998, 18(2):122-125.
[2] Devroey P, Fauser B C, Platteau P, et al. Induction of multiple follicular development by a single dose of long-acting recombinant follicle-stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. J Clin Endocrinol Metab, 2004, 89(5): 2062-2070.
[3] Duijkers I J, Klipping C, Boerrigter PJ, et al. Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females. Hum Reprod, 2002, 17(8): 1987-1993.
[4] Ben-Menahem D, Grotjan H E. Strategies for construction of luteinizing hormone beta subunit analogs with carboxyl terminal extensions in non-primate, non-equid mammalian species. Mol Cell Endocrinol, 2007, 260-262: 205-211.
[5] Seyhan A, Ata B. The role of corifollitropin alfa in controlled ovarian stimulation for IVF in combination with GnRH antagonist. Int J Womens Health, 2011, 3: 243-255.
[6] Fauser B C, Mannaerts B M, Devroey P, et al. Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency. Hum Reprod Update, 2009, 15(3): 309-321.
[7] Dumont J A, Low S C, Peters R T, et al. Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics. BioDrugs, 2006, 20(3): 151-160.
[8] Suzuki T, Ishii-Watabe A, Tada M, et al. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol, 2010, 184(4): 1968-1976.
[9] Bitonti A J, Dumont J A, Low S C, et al. Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci U S A, 2004, 101(26): 9763-9768.
[10] Council of Europe Strasbourg. European Pharmacopoeia. 2008,Vol V:69.
[11] 国家药典委员会. 中华人民共和国药典. 二部. 北京:中国医药科技出版社. 2010,附录 XIV130-147. Chinese Pharmacopoeia Commission. Pharmacopoeia of People's Republic of China Volume II. Beijing:China Medical Science Press.2010,appendix XIV130-147.
[12] 国家药典委员会. 中华人民共和国药典. 二部. 北京:中国医药科技出版社. 2010,附录VI C35. Chinese Pharmacopoeia Commission. Pharmacopoeia of People's Republic of China Volume II. Beijing:China Medical Science Press.2010,appendix VI C35.
[13] 国家药典委员会. 中华人民共和国药典. 二部. 北京:中国医药科技出版社. 2010,附录IV D24. Chinese Pharmacopoeia Commission. Pharmacopoeia of People's Republic of China Volume II. Beijing:China Medical Science Press.2010,appendix VI D24
[14] Hakola K, Haavisto A M, Pierroz D D, et al. Recombinant forms of rat and human luteinizing hormone and follicle-stimulating hormone; comparison of functions in vitro and in vivo. J Endocrinol, 1998, 158(3): 441-448.
[15] Verbost P, Sloot W N, Rose U M, et al. Pharmacologic profiling of corifollitropin alfa, the first developed sustained follicle stimulant. Eur J Pharmacol, 2011,651(1-3):227-233.
[16] Mascarenhas M N, Flaxman S R, Boerma T, et al. National, regional, and global trends in infertility prevalence since 1990: a systematic analysis of 277 health surveys. PLoS Med, 2012, 9(12): e1001356.
[17] Lo K M, Sudo Y, Chen J, et al. High level expression and secretion of Fc-X fusion proteins in mammalian cells. Protein Eng, 1998, 11(6): 495-500.
[18] Lightle S, Aykent S, Lacher N, et al. Mutations within a human IgG2 antibody form distinct and homogeneous disulfide isomers but do not affect Fc gamma receptor or C1q binding. Protein Sci, 2010, 19(4): 753-762. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
